Mylocar 60mg Injection: Second-Generation Proteasome Inhibition for Relapsed Multiple Myeloma
Are you searching for a reliable Myolcar 60 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced hematological therapeutics. We cater to high-demand healthcare markets in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, providing seamless B2B pharmaceutical exports and reliable cold chain delivery.
Detailed Product Overview: What is Mylocar 60mg?
Mylocar 60 mg Injection is a sterile, prescription-strength powder for intravenous infusion containing the active pharmaceutical ingredient Carfilzomib.
Mylocar is specifically engineered to provide irreversible, targeted binding to myeloma cells.
It offers a critical intervention for adult patients who have relapsed (cancer returned) or become refractory (unresponsive) to previous lines of therapy.
Mylocar 60 mg is clinically indicated for:
Relapsed or Refractory Multiple Myeloma (RRMM): Used as a monotherapy for patients who have undergone one or more previous cancer treatments.
Combination Regimens: Often prescribed synergistically with Dexamethasone or alongside Lenalidomide and Dexamethasone to dramatically improve progression-free survival.
Advanced Hematological Care: Acts as a salvage therapy when initial treatments (like bortezomib or immunomodulatory agents) fail.
Mechanism of Action: How Mylocar 60mg Works
Mylocar targets the metabolic "waste disposal" system within cancer cells.
Irreversible Proteasome Blockade: Carfilzomib binds tightly to the 20S proteasome, an enzyme complex that breaks down unneeded or damaged proteins in a cell.
Toxic Protein Overload: Myeloma cells produce excessive amounts of paraproteins (monoclonal proteins). Without active proteasomes to break them down, these proteins pile up rapidly.
Apoptosis (Cell Death): This cellular "congestion" triggers extreme stress within the myeloma cell, forcing it to undergo apoptosis (programmed cell death) while leaving most normal cells relatively unharmed.
Dosage, Administration, and Cold Chain Management
Administration: It must be administered strictly as an Intravenous (IV) Infusion by trained oncology professionals.
It is not for self-administration. Hydration Protocol: Adequate pre-dose and post-dose hydration is mandatory to protect renal function and prevent Tumor Lysis Syndrome (TLS).
Temperature Stability: As a high-potency biotech product, Mylocar requires strict cold chain storage (between 2°C and 8°C) from the Indian facility to the destination country.
Clinical Side Effects & Safety Monitoring
Patients undergoing Mylocar therapy should be regularly screened for the following:
Fatigue, pyrexia (fever), and nausea.
Myelosuppression: Reductions in red blood cells (anemia) and platelets (thrombocytopenia).
Cardiovascular events (blood pressure tracking is essential).
Renal and hepatic profiles via periodic laboratory checks.
Why Partner with Ernest Oncology for Global Supply?
Cold Chain Logistics Mastery: Validated shipping protocols to maintain strict thermal compliance for the USA, UK, UAE, Australia, and South Africa.
Authentic Sourcing: Direct procurement from GMP-certified facilities, ensuring product integrity for every exporter from India shipment.
Bulk Stock Availability: Reliable fulfillment of 60mg vials to avoid clinical treatment gaps.
Regulatory & B2B Paperwork: Full export documentation and transparent track-and-trace shipping.
Contact Ernest Oncology—Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
Websites:
www.oncologymedicinesupplier.com Business Type: Exporter | Bulk Supplier | Distributor
WhatsApp: +91 93599 02383
Direct Link:
Chat on WhatsApp
